Companion Diagnostics For Breakthrough Drugs Also Getting Swift Attention, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough drugs from coming to market.